Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefpodoxime Proxetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | PPARG | P37231 | 2/20 | 0.66 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.66 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.66 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.66 |
| ▸ | ALB | P02768 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | APEX1 | P27695 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefpodoxime Proxetil SCHEMBL4410291 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL7810065 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL7256264 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL8687125 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL614583 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL379709 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL27071 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL6136644 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL22330291 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL5266189 | 0.99 | PTGS1 (0.99) | PTGS1ABCB11PDE4DNR1I2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3230500-B1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | TEPHA INC (US) | 2025-06-18 | — | — | EP | claimed |
| EP-3678715-B1 | CALENDERED SURGICAL MESHES COMPRISING POLYHYDROXYALKANOATES | TEPHA INC (US) | 2024-10-30 | — | — | EP | claimed |
| EP-3802062-B1 | METHODS FOR 3D PRINTING OF POLY-4-HYDROXYBUTYRATE | TEPHA INC (US) | 2024-09-18 | — | — | EP | claimed |
| EP-4045040-B1 | NITROGEN CONTAINING BICYCLIC COMPOUNDS | WOCKHARDT LTD (IN) | 2023-04-05 | — | — | EP | claimed |
| EP-3452122-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2023-03-22 | — | — | EP | claimed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | claimed |
| EP-3659585-B1 | COMPOSITION FOR DELIVERING PHYSIOLOGICALLY ACTIVE INGREDIENTS INTO BLOOD VESSEL | LEMONEX INC (KR) | 2025-06-25 | — | — | EP | disclosed |
| US-20250032414-A1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | LEMONEX INC. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-12186740-B2 | Kits comprising containers with at least one solid catalytically active compound, and their uses in solid state reaction | RD&CResearch, Development &Consulting GmbH (AT) | 2025-01-07 | — | — | US | disclosed |
| US-12138346-B2 | Physiologically active substance carrier | LEMONEX INC. (KR) | 2024-11-12 | — | — | US | disclosed |
| EP-4382109-A1 | USE OF A COMPOSITE MATERIAL | Heraeus Medical GmbH (DE) | 2024-06-12 | — | — | EP | disclosed |
| US-20240041771-A1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | LEMONEX INC. (KR) | 2024-02-08 | — | — | US | disclosed |
| US-11793757-B2 | Physiologically active substance carrier | LEMONEX INC. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-20230293656-A1 | BACTERIUM CAPABLE OF INDUCING TH1 CELLS | KEIO UNIVERSITY (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-4213862-A1 | IMPROVED PHARMACEUTICAL PREPARATION | CytoPharma Ltd. (GB) | 2023-07-26 | — | — | EP | disclosed |
| US-20230190793-A1 | Pharmaceutical Preparation for Use in the Treatment of Systemic Inflammatory Response Syndrome (SIRS) | CYTOPHARMA GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| US-11285133-B2 | 2- or 3-imidazolines as carbapenemases inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-03-29 | — | — | US | disclosed |
| WO-2022058203-A1 | IMPROVED PHARMACEUTICAL PREPARATION | CYTOPHARMA GMBH (DE) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190793-A1 | Pharmaceutical Preparation for Use in the Treatment of Systemic Inflammatory Response Syndrome (SIRS) | TNF, TSLP, IL1B | PTGS1 39/4885ABCB11 454/4885PDE4D 1732/4885 |
| US-11285133-B2 | 2- or 3-imidazolines as carbapenemases inhibitors | PADI3, PADI1, RPIA | PTGS1 2972/4885ABCB11 374/4885PDE4D 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.